The estimated Net Worth of Hazel M Aker is at least $195 Mille dollars as of 21 July 2020. Hazel Aker owns over 41,972 units of Oncternal Therapeutics stock worth over $195,231 and over the last 5 years Hazel sold ONCT stock worth over $0.
Sign up
Hazel Aker ONCT stock SEC Form 4 insiders trading
Hazel has made over 1 trades of the Oncternal Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Hazel bought 41,972 units of ONCT stock worth $99,893 on 21 July 2020.
The largest trade Hazel's ever made was buying 41,972 units of Oncternal Therapeutics stock on 21 July 2020 worth over $99,893. On average, Hazel trades about 10,493 units every 0 days since 2019. As of 21 July 2020 Hazel still owns at least 46,987 units of Oncternal Therapeutics stock.
You can see the complete history of Hazel Aker stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Hazel Aker's mailing address?
Hazel's mailing address filed with the SEC is 12230 EL CAMINO REAL, SUITE 300, , SAN DIEGO, CA, 92130.
Insiders trading at Oncternal Therapeutics
Over the last 5 years, insiders at Oncternal Therapeutics have traded over $26,287 worth of Oncternal Therapeutics stock and bought 1,526,610 units worth $3,062,129 . The most active insiders traders include Pharmaceutical (Usa) Inc.Sh..., Charles Theuer e Robert James Wills. On average, Oncternal Therapeutics executives and independent directors trade stock every 68 days with the average trade being worth of $302,970. The most recent stock trade was executed by Robert James Wills on 8 April 2024, trading 3,086 units of ONCT stock currently worth $27,651.
What does Oncternal Therapeutics do?
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting receptor-tyrosine kinase-like Orphan Receptor 1. The company is headquartered in San Diego, California.
What does Oncternal Therapeutics's logo look like?
Complete history of Hazel Aker stock trades at Oncternal Therapeutics
Oncternal Therapeutics executives and stock owners
Oncternal Therapeutics executives and other stock owners filed with the SEC include:
-
James Breitmeyer,
President, Chief Executive Officer, Director -
Dr. James B. Breitmeyer,
Pres, CEO & Director -
Frank Hsu,
Chief Medical Officer -
Dr. Gunnar F. Kaufmann Ph.D.,
Chief Scientific Officer -
Charles Theuer,
Independent Director -
William LaRue,
Independent Director -
Daniel Kisner,
Independent Director -
Michael Carter,
Independent Director -
Nakanishi Xin,
Director -
Robert Wills,
Director -
Man Cho,
Director -
Igor Bilinsky,
Chief Business Officer -
Gunnar Kaufmann,
Chief Scientific Officer -
Richard Vincent,
Chief Financial Officer, Treasurer, Secretary -
David Hale,
Independent Chairman of the board -
Dr. Steven Hamburger Ph.D.,
Sr. VP of Regulatory Affairs & Quality Assurance -
Dr. Salim Yazji,
Chief Medical Officer -
Pablo Urbaneja,
Sr. VP of Corp. Devel. -
Chase C. Leavitt,
Gen. Counsel -
Dr. Rajesh Krishnan Ph.D.,
Chief Technology Officer -
Rajesh Krishnan,
CTO/CSO -
Pharmaceutical (Usa) Inc.Sh...,
-
Yanjun Liu,
Director -
Hazel M Aker,
Legal Counsel -
Pharmaceutical (Usa) Inc. S...,
10% owner -
Rosemary Mazanet,
-
Jinzhu Ph D Chen,
Director -
Chase C. Leavitt,
General Counsel/Secretary -
Salim Yazji,
Chief Medical Officer -
Jill De Simone,